Abstract
In our animal studies, we have reported that bone marrow cells (BMCs) infused via a peripheral vein efficiently repopulate the cirrhotic liver. Repopulated BMCs produce collagenases including matrix metalloproteinase-9. As a result, we observed reduced liver fibrosis, elevated serum albumin levels, and a significant increase in survival. Based on these data, we have begun “autologous bone marrow cell infusion (ABMi) therapy” using non-cultured autologous whole BMCs. This therapy was officially approved as “advanced medical technology B” in Japan. However, ABMi therapy involves bone marrow (BM) aspiration under general anesthesia. We therefore developed a less-invasive liver regeneration therapy using cultured autologous mesenchymal stem cells (MSCs) isolated from a small amount of BM fluid aspirated under local anesthesia. We showed that peripheral infusion of cultured human BMCs reduces hepatic fibrosis in immunodeficient cirrhotic mice, consistent with the maintenance of redox homeostasis in hepatic stellate cells and hepatocytes. To evaluate safety using canine models, cultured autologous MSCs were administered to the same subject in approximately three times the quantity and ten times the concentration used in humans. We then constructed a cell-processing facility with a new isolator system to confer protection from hepatitis virus. Here, we summarize the current status and prospects for our liver regeneration therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, et al. Liver from bone marrow in humans. Hepatology. 2000;32:11–6.
Gilchrist ES, Plevris JN. Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl. 2010;16:118–29.
Stutchfield BM, Forbes SJ, Wigmore SJ. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl. 2010;16:827–36.
Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2012;28:203–8.
Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M’Hamdi H, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006;24:1822–30.
Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008;48:221–9.
Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet. 1999;353:555.
Park CH, Bae SH, Kim HY, Kim JK, Jung ES, Chun HJ, Song MJ, et al. A pilot study of autologous CD34-depleted bone marrow mononuclear cell transplantation via the hepatic artery in five patients with liver failure. Cytotherapy. 2013;15:1571–9.
Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, Park HJ, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int. 2014;34:33–41.
Xu L, Gong Y, Wang B, Shi K, Hou Y, Wang L, Lin Z, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol. 2014;29:1620–8.
Terai S, Sakaida I, Yamamoto N, Omori K, Wratanabe T, Ohata S, Katada T, et al. An in vivo model for monitoring the transdifferentiation of bone marrow cells into functional hepatocytes. J Biochem. 2003;134(4):551–8.
Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, Okita K. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004;40:1304–11.
Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006;24:2292–8.
Terai S, Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhosis patients. J Hepatobiliary Pancreat Sci. 2011;18:23–5.
Kim JK, Park YN, Kim JS, Park MS, Paik YH, Seok JY, Chung YE, et al. Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver _cirrhosis. Cell Transplant. 2010;19:1237–46.
Saito T, Okumoto K, Haga H, Nishise Y, Ishii R, Sato C, Watanabe H, et al. Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis. Stem Cells Dev. 2011;20:1503–10.
Tanimoto H, Terai S, Taro T, Murata Y, Fujisawa K, Yamamoto N, Sakaida I. Improvement of liver fibrosis by infusion of cultured cells derived f‑rom human bone marrow. Cell Tissue Res. 2013;354:717–28.
Acknowledgments
This study was supported by Grants-in-Aid for scientific research from the Japan Society for the Promotion of Science (JSPS); Ministry of Health, Labour and Welfare, Health and Labour Sciences Research Grants; Japan Science and Technology Agency (JST); and the project of realization of regenerative medicine and highway.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Takami, T., Terai, S., Sakaida, I. (2016). Liver Regeneration Therapy Using Autologous Bone Marrow-Derived Cells for Cirrhotic Patients. In: Terai, S., Suda, T. (eds) Gene Therapy and Cell Therapy Through the Liver. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55666-4_3
Download citation
DOI: https://doi.org/10.1007/978-4-431-55666-4_3
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55665-7
Online ISBN: 978-4-431-55666-4
eBook Packages: MedicineMedicine (R0)